Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial

Mafalda Oliveira, Denys Pominchuk, Zbigniew Nowecki, Erika Hamilton, Yaroslav Kulyaba, Timur Andabekov, Yevhen Hotko, Tamar Melkadze, Gia Nemsadze, Patrick Neven, Vladimir Vladimirov, Claudio Zamagni, Hannelore Denys, Frédéric Forget, Zsolt Horváth, Alfiya Nesterova, Maxine Ajimi, Bistra Kirova, Teresa Klinowska, Justin P.O. Lindemann, Delphine Lissa, Alastair Mathewson, Christopher J. Morrow, Zuzana Traugottova, R. van Zyl, Ekaterine Arkania

The Lancet Oncology, 2024